PDL BioPharma (PDLI) Tops Estimates

Shares of PDL BioPharma, Inc. (PDLI) rallied after the pharmaceutical firm released its earnings results on Monday. The company reported Q2’14 EPS/$0.52 vs $0.46 consensus on $163 million in revenue, up about 10% from $148.5 million a year ago. For the six month period ended June 30, 2014 the company saw revs increase by 23% to $299.6 million, compared with $244.1 million for the first six months of 2013.

Ending the day at $9.32, shares of PDL BioPharma climbed 5% during extended hours after a total of more than 3.7 million shares changed hands, continuing an upward climb that has added about 31% in the stock’s value since February 5.

Speaking from a valuation-measure perspective, shares of PDL BioPharma have a trailing-12 P/E of 5.37, a forward P/E of 4.57 and a P/E to growth ratio of 0.32. Price/sales for the t-12 period is at 3.10, while EPS is at $1.74. The company has a market cap of $1.50 billion and a median Wall Street price target of $7.00 with a high target of $8.00.

Profitability-wise, PDL’s t-12 profit margin currently stands at 57.86% while operating ones are at 90.89%. The company reported $337.59 million in cash vs. $523.14 in debt in its most recent quarter. PDLI was up 4.51% at $9.74 recently, within a 52-week range of $7.38 to $10.20. Ticker currently prints a one year return of about 17% and a year-to-date return of around 10.43%.

The chart below shows where the equity has traded over the last 52 weeks, with the 50-day and 200-day MAs included.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.